Morphology and etiopathogenesis of the abdominal aortic aneurysm

1. Gillum RF. Epidemiology of aortic aneurysm in the United States. J Clin Epidemiol 1995; 48: 1289–1298.

2. Eickhoff JH. Incidence of diagnosis, operation and death from abdominal aortic aneurysms in Danish hospitals: results from a nation-wide survey, 1977–1990. Eur J Surg 1993; 159: 619–623.

3. Vardulaki KA, et al. Incidence among men of asymptomatic abdominal aortic aneurysms: estimates from 500 screen detected cases. J Med Screen 1999; 6: 50–54.

4. Powell JT, Brady AR. Detection, management, and prospects for the medical treatment of small abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2004; 24: 241–245.

5. Cowan JA Jr, et al. Epidemiology of aortic aneurysm repair in the United States from 1993 to 2003. Ann N Y Acad Sci 2006; 1085: 1–10.

6. Lederle FA, et al. Rupture rate of large abdominal aortic aneurysms in patients refusing or unfit for elective repair. JAMA 2002; 287: 2968–2972.

7. Bengtsson H, Bergqvist D. Ruptured abdominal aortic aneurysm: a population-based study. J Vasc Surg 1993; 18: 74–80.

8. Heikkinen M, et al. Ruptured abdominal aortic aneurysm in a well-defined geographic area. J Vasc Surg 2002; 36: 291–296.

9. Mealy K, Salman A. The true incidence of ruptured abdominal aortic aneurysms. Eur J Vasc Surg 1988; 2: 405–408.

10. Kantonen I, et al. Mortality in ruptured abdominal aortic aneurysms. The Finnvasc Study Group. Eur J Vasc Endovasc Surg 1999; 17: 208–212.

11. Darling RC, et al. Autopsy study of unoperated abdominal aortic aneurysms. The case for early resection. Circulation 1977; 56: II161–164.

12. Kent KC, et al. Screening for abdominal aortic aneurysm: a consensus statement. J Vasc Surg 2004; 39: 267–269.

13. Šebesta P. Břišní aorta a pánevní tepny. In: Krajíček M, et al. Chirurgická a intervenční léčba cévních onemocnění. Praha: Grada Publishing 2007; 192.

14. Třeška V, et al. Aneuryzma břišní aorty. Praha: Grada Publishing 1999.

15. Wolinsky H, Glagov S. Structural Basis for the Static Mechanical Properties of the Aortic Media. Circ Res 1964; 14: 400–413.

16. Dingemans KP, et al. Extracellular Matrix of the Human Aortic media: An Ultrastructural Histochemical and Immunohistochemical Study of the Adult Aortic Media. Anat Rec 2000; 258: 1–14.

17. Stintzing S, et al. Differentiation patterning of vascular smooth muscle cells (VSMC) in atherosclerosis. Virchows Arch 2009; 455: 171–185.

18. Shanahan CM, Weissberg PL. Smooth muscle cell phenotypes in atherosclerotic lesions. Curr Opin Lipidol 1999; 10: 507–513.

19. Grabenwöger M, et al. Endothelialization of biosynthetic vascular prostheses after laser perforation. Ann Thorac Surg 1998; 66: 110–114.

20. Stary HC. Natural History and Histological Classification of Atherosclerotic Lesions. An Update. Arterioscler Tromb Vasc Biol 2000; 20: 1177–1178.

21. Stary HC. Slide atlas of atherosclerosis: Progression and regression. CD-ROM. New York: Parthenon Publishing 2002.

22. Virmani R, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20: 1262–1275.

23. Tonar Z, et al. Kvantitativní popis aterosklerotických lézí na úrovni optické mikroskopie. Cor Vasa 2007; 49: 95–101.

24. Kočová J. Overall staining of connective tissue and the muscular layer of vessels. Folia Morphologica 1970; 18: 293–295.

25. Koch AE, et al. Human Abdominal Aortic Aneurysms Immunophenotypic Analysis Suggesting an Immune-mediated Response. American Journal of Pathology 1990; 137: 1199–1213.

26. Třeška V, et al. Inflammation in the wall of abdominal aortic aneurysm and its role in the symptomatology of aneurysm. Cytokines, Cellular & Molecular Therapy 2002; 7: 91–97.

27. Tonar Z, et al. Stereological tools for quantitative microscopy of the aortic wall with focus on the abdominal aortic aneurysm (2010). In: Méndez-Vilas A, Díaz J (Eds.). Microscopy: Science, Technology, Applications and Education. Applications in Biology and Medicine. Vol. 2. Formatex Research Centre, Badajoz, 926–935.

28. Holmes DR, et al. Medial neovascularization in abdominal aortic aneurysms: a histopathologic marker of aneurysmal degeneration with pathophysiologic implications. J Vasc Surg 1995; 21: 761–771.

29. Choke E, et al. A review of biological factors implicated in abdominal aortic aneurysm rupture. Eur J Vasc Endovasc Surg 2005; 30: 227–244.

30. Dalman RL. Oxidative stress and abdominal aneurysms: how aortic hemodynamic conditions may influence AAA disease. Cardiovasc Surg 2003; 11: 417–419.

31. Buschmann I, Schaper W. Arteriogenesis versus angiogenesis: two mechanisms of vessel growth. News in Physiological Sciences 1999; 14: 121–125.

32. Harter LP, et al. Ultrasonic evaluation of abdominal aortic thrombus. J Ultrasound Med 1982; 1: 315–318.

33. Falk E. Dynamics in thrombus formation. Ann N Y Acad Sci 1992; 667: 205–223.

34. Touat Z, et al. Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneurysm evolution. Am J Pathol 2006; 168: 1022–1030.

35. Adolph R, et al. Cellular content and permeability of intraluminal thrombus in abdominal aortic aneurysm. J Vasc Surg 1997; 25: 916–926.

36. Tilson MD, Seashore MR. Human genetics of the abdominal aortic aneurysm. Surg Gynecol Obstet 1984; 158: 129–132.

37. Johansen K, Koepsell T. Familial tendency for abdominal aortic aneurysms. JAMA 1986; 256: 1934–1936.

38. Baird PA, et al. Sibling risks of abdominal aortic aneurysm. Lancet 1995; 346: 601–604.

39. Vardulaki KA, et al. Quantifying the risk of hypertension, age, sex and smoking in patients with abdominal aortic aneurysm. Br J Surg 2000; 87: 195–200.

40. Brady AR, et al. Abdominal Aortic Aneurysm Expansion: Risk Factors and Time Intervals for Surveillance. Circulation 2004; 110: 16–21.

41. Blanchard JF, et al. Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study: The TromsŅ Study. Am J Epidemiol 2001; 154: 236–244.

42. Choke E, et al. Review of Biological Factors Implicated in Abdominal Aortic Aneurysm Rupture. Eur J Vasc Endovasc Surg 2005; 30: 227–244.

43. Thompson A, et al. An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance. J Vasc Surg 2010; 52: 55–61.

44. LaMorte WW, et al. Racial differences in the incidence of femoral bypass and abdominal aortic aneurysmectomy in Massachusetts: relationship to cardiovascular risk factors. J Vasc Surg 1995; 21: 422–431.

45. Humphrey JD, Taylor CA. Intracranial and abdominal aortic aneurysms: similarities, differences, and need for a new class of computational models. Annu Rev Biomed Eng 2008; 10: 221–246.

46. Nichols KB, Rodriguez AA. Comparison of and investigation into the size effects on the rotational dynamics of two spherical molecules: CCl4 and C60. J Phys Chem A 2005; 109: 3009–3014.

47. Clifton MA. Familial abdominal aortic aneurysms. Br J Surg 1977; 64: 765–766.

48. Salo JA, et al. Familial occurrence of abdominal aortic aneurysm. Ann Intern Med 1999; 130: 637–642.

49. Baird PA, et al. Sibling risks of abdominal aortic aneurysm. Lancet 1995; 346: 601–604.

50. Tilson MD, Seashore MR. Fifty families with abdominal aortic aneurysms in two or more first-order relatives. Am J Surg 1984; 147: 551–553.

51. Majumder PP, et al. On the inheritance of abdominal aortic aneurysm. Am J Hum Genet 1991; 48: 164–170.

52. Kuivaniemi H, et al. Familial abdominal aortic aneurysms: collection of 233 multiplex families. J Vasc Surg 2003; 37: 340–345.

53. Pola R, et al. Abdominal aortic aneurysm in normotensive patients: association with angiotensin-converting enzyme gene polymorphism. Eur J Vasc Endovasc Surg 2001; 21: 445–449.

54. Jones K, et al. The influence of 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene promoter on the incidence, growth and operative risk of abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2002; 23: 421–425.

55. Strauss E, et al. Increased risk of the abdominal aortic aneurysm in carriers of the MTHFR 677T allele. J Appl Genet 2003; 44: 85–93.

56. Fatini C, et al. eNOS G894T polymorphism as a mild predisposing factor for abdominal aortic aneurysm. J Vasc Surg 2005; 42: 415–419.

57. Rasmussen TE, et al. Human leukocyte antigen class II immune response genes, female gender, and cigarette smoking as risk and modulating factors in abdominal aortic aneurysms. J Vasc Surg 2002; 35: 988–993.

58. Sandford RM, et al. The genetic basis of abdominal aortic aneurysms: a review. Eur J Vasc Endovasc Surg 2007; 33: 381–390.

59. Gregory AK, et al. Features of autoimmunity in the abdominal aortic aneurysm. Arch Surg 1996; 131: 85–88.

60. Tambiah J, et al. Provocation of experimental aortic inflammation and dilatation by inflammatory mediators and Chlamydia pneumoniae. Br J Surg 2001; 88: 935–940.

61. Hance KA, et al. Monocyte chemotactic activity in human abdominal aortic aneurysms: role of elastin degradation peptides and the 67-kD cell surface elastin receptor. J Vasc Surg 2002; 35: 254–261.

62. Bown MJ, et al. The role of cytokine gene polymorphisms in the pathogenesis of abdominal aortic aneurysms: a case-control study. J Vasc Surg 2003; 37: 999–1005.

63. Juvonen J, et al. Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1997; 17: 2843–2847.

64. Dawson J, et al. Circulating cytokines in patients with abdominal aortic aneurysms. Ann N Y Acad Sci 2006; 1085: 324–326.

65. Rohde LE, et al. Plasma concentrations of interleukin-6 and abdominal aortic diameter among subjects without aortic dilatation. Arterioscler Thromb Vasc Biol 1999; 19: 1695–1699.

66. Houard X, et al. Mediators of neutrophil recruitment in human abdominal aortic aneurysms. Cardiovasc Res 2009; 82: 532–541.

67. Middleton RK, et al. Characterisation of Interleukin-8 and monocyte chemoattractant protein-1 expression within the abdominal aortic aneurysm and their association with mural inflammation. Eur J Vasc Endovasc Surg 2009; 37: 46–55.

68. Třeška V, et al. Cytokines as plasma markers of abdominal aortic aneurysm. Clin Chem Lab Med 2000; 38: 1161–1164.

69. Davis VA, et al. Cytokine pattern in patients with abdominal aortic aneurysm. Vasc Endovascular Surg 2011; 45: 63–68.

70. Muehling BM, et al. In vivo study on the expression pattern of resistin in patients with abdominal aortic aneurysm. Vasc Endovascular Surg 2011; 45: 63–68.

71. Pan JH, et al. Macrophage migration inhibitory factor is associated with aneurysmal expansion. J Vasc Surg 2003; 37: 628–635.

72. Loftus IM, Thompson MM. The role of matrix metalloproteinases in vascular disease. Vasc Med 2002; 7: 117–133.

73. Jones GT, et al. Functional matrix metalloproteinase-9 polymorphism (C-1562T) associated with abdominal aortic aneurysm. J Vasc Surg 2003; 38: 1363–1367.

74. Eriksson P, et al. Genotype-phenotype relationships in an investigation of the role of proteases in abdominal aortic aneurysm expansion. Br J Surg 2005; 92: 1372–1376.

75. Irizarry E, et al. Demonstration of interstitial collagenase in abdominal aortic aneurysm disease. J Surg Res 1993; 54: 571–574.

76. Knox JB, et al. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation 1997; 95: 205–212.

77. Davis V, et al. Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 1998; 18: 1625–1633.

78. Crowther M, et al. Increased matrix metalloproteinase 2 expression in vascular smooth muscle cells cultured from abdominal aortic aneurysms. J Vasc Surg 2000; 32: 575–583.

79. Erdozain OJ, et al. Hypoxia in abdominal aortic aneurysm supports a role for HIF-1α and Ets-1 as drivers of matrix metalloproteinase upregulation in human aortic smooth muscle cells. J Vasc Res 2011; 48: 163–170.

80. Elmore JR, et al. Expression of matrix metalloproteinases and TIMPs in human abdominal aortic aneurysms. Ann Vasc Surg 1998; 12: 221–228.

81. Fontaine V, et al. Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms. Am J Pathol 2002; 161: 1701–1710.

82. Thompson RW, et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 1995; 96: 318–326.

83. Mao D, et al. Expression of collagenase-3 (MMP-13) in human abdominal aortic aneurysms and vascular smooth muscle cells in culture. Biochem Biophys Res Commun 1999; 261: 904–910.

84. Tamarina NA, et al. Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta.Surgery. 1997; 122: 264–271.

85. Elmore JR, et al. Expression of matrix metalloproteinases and TIMPs in human abdominal aortic aneurysms. Ann Vasc Surg 1998; 12: 221–228.

86. Defawe OD, et al. TIMP-2 and PAI-1 mRNA levels are lower in aneurysmal as compared to athero-occlusive abdominal aortas. Cardiovasc Res 2003; 60: 205–213.

87. Wilson WR, et al. Plasma matrix metalloproteinase levels do not predict tissue levels in abdominal aortic aneurysms suitable for elective repair. Vascular 2008; 16: 248–252.

88. Hovsepian DM, et al. Elevated plasma levels of matrix metalloproteinase-9 in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease. J Vasc Interv Radiol 2000; 11: 1345–1352.

89. Eugster T, et al. Aminoterminal propeptide of type III procollagen and matrix metalloproteinases-2 and -9 failed to serve as serum markers for abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2005; 29: 378–382.

90. Lindholt JS, et al. The plasma level of matrix metalloproteinase 9 may predict the natural history of small abdominal aortic aneurysms. A preliminary study. Eur J Vasc Endovasc Surg 2000; 20: 281–285.

91. Abdul-Hussien H, et al. Collagen degradation in the abdominal aneurysm: a conspiracy of matrix metalloproteinase and cysteine collagenases. Am J Pathol 2007; 170: 809–817.

92. Abdul-Hussien H, et al. The pathophysiology of abdominal aortic aneurysm growth: corresponding and discordant inflammatory and proteolytic processes in abdominal aortic and popliteal artery aneurysms. J Vasc Surg 2010; 51: 1479–1487.

93. Shi GP, et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 1999; 104: 1191–1197.

94. Lindholt JS, et al. Cystatin C deficiency is associated with the progression of small abdominal aortic aneurysms. Br J Surg 2001; 88: 1472–1475.

95. Lindholt JS, et al. Plasma levels of plasmin-antiplasmin-complexes are predictive for small abdominal aortic aneurysms expanding to operation-recommendable sizes. J Vasc Surg 2001; 34: 611–615.

96. Lindholt JS, et al. Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2003; 25: 546–551.

97. Lindholt JS. Activators of plasminogen and the progression of small abdominal aortic aneurysms. Ann N Y Acad Sci 2006; 1085: 139–150.

98. Kríková V, et al. Quantification of plasminogen activator inhibitor type 1 in the aortic wall. Int Angiol 2009; 28: 44–49.

99. Lindholt JS, et al. Systemic levels of cotinine and elastase, but not pulmonary function, are associated with the progression of small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2003; 26: 418–422.

100. Molacek J, et al. Optimization of the model of abdominal aortic aneurysm-experiment in an animal model. J Vasc Res 2009; 46: 1–5.

101. Kazi M, et al. Influence of intraluminal thrombus on structural and cellular composition of abdominal aortic aneurysm wall. J Vasc Surg 2003; 38: 1283–1292.

102. Sakalihasan N, et al. Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms. J Vasc Surg 1996; 24: 127–133.

103. Fontaine V, et al. Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms. Am J Pathol 2002; 161: 1701–1710.

104. Wolf YG, et al. Computed tomography scanning findings associated with rapid expansion of abdominal aortic aneurysms. J Vasc Surg. 1994; 20: 529–535.

105. Stenbaek J, et al. Growth of Thrombus may be a Better Predictor of Rupture than Diameter in Patients with Abdominal Aortic Aneurysms. Eur J Vasc Endovasc Surg 2000; 20: 466–469.

106. Hans SS, et al. Size and location of thrombus in intact and ruptured abdominal aortic aneurysms. J Vasc Surg 2005; 41: 584–588.

107. Lindholt JS, et al. A review of Chlamydia pneumoniae and atherosclerosis. Eur J Vasc Endovasc Surg 1999; 17: 283–289.

108. Lindholt JS, Shi GP. Chronic inflammation, immune response, and infection in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2006; 31: 453–463.

109. Lindholt JS, et al. Indicators of infection with Chlamydia pneumoniae are associated with expansion of abdominal aortic aneurysms. J Vasc Surg 2001; 34: 212–215.

110. Lindholt JS, et al. Vascular surgical society of great britain and ireland: immunoglobulin A antibodies against chlamydia pneumoniae are associated with expansion of small abdominal aortic aneurysms and declining ankle blood pressure. Br J Surg 1999; 86: 698.

111. Falkensammer B, et al. Lack of microbial DNA in tissue specimens of patients with abdominal aortic aneurysms and positive Chlamydiales serology. Eur J Clin Microbiol Infect Dis 2007; 26: 141–145.

112. Becker RC. Emerging paradigms, platforms, and unifying themes in biomarker science. J Am Coll Cardiol 2007; 50: 1777–1780.

113. Urbonavicius S, et al. Potential circulating biomarkers for abdominal aortic aneurysm expansion and rupture-a systematic review. Eur J Vasc Endovasc Surg 2008; 36: 273–280.

114. Lindholt JS, et al. Serum-elastin-peptides as a predictor of expansion of small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 1997; 14: 12–16.

115. Lindholt JS, et al. Serum elastin peptides in the preoperative evaluation of abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2001; 22: 546–550.

116. Satta J, et al. Aminoterminal propeptide of type III procollagen in the follow-up of patients with abdominal aortic aneurysms. J Vasc Surg 1997; 25: 909–915.

117. Treska V, Topolcan O. Plasma and tissue levels of collagen types I and III markers in patients with abdominal aortic aneurysms. Int Angiol 2000; 19: 64–68.

118. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. The UK Small Aneurysm Trial Participants Lancet 1998; 352: 1649–1655.

119. Filipovic M, et al. Elective surgery for aortic abdominal aneurysm: comparison of English outcomes with those elsewhere. J Epidemiol Community Health 2007; 61: 226–231.

120. McCarthy RJ, et al. Recommendations for screening intervals for small aortic aneurysms. Br J Surg 2003; 90: 821–826.

121. Cooper DG, et al. Role of medical intervention in slowing the growth of small abdominal aortic aneurysms. Postgrad Med J 2009; 85: 688–692.

122. Linhart A, et al. Angiologie. In: Češka R. et al. Interna. Praha: Triton 2010; 189–190.

123. Ricci MA, et al. Effects of hypertension and propranolol upon aneurysm expansion in the Anidjar/Dobrin aneurysm model. Ann N Y Acad Sci 1996; 800: 89–96.

124. Liao S, et al. Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg 2001; 33: 1057–1064.

125. Biancari F, et al. Ten-year outcome of patients with very small abdominal aortic aneurysm. Am J Surg 2002; 183: 53–55.

126. Hackam DG, et al. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet 2006; 368: 659–665.

127. Wilson WR, et al. HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2005; 30: 259–262.

128. Steinmetz EF, et al.. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg 2005; 241: 92–101.

129. Schouten O, et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 2006; 32: 21–26.

130. Mosorin M, et al. The use of statins and fate of small abdominal aortic aneurysms. Interact Cardiovasc Thorac Surg 2008; 7: 578–581.

131. Petrinec D, et al. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg 1996; 23: 336–346.

132. Vammen S, et al. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br J Surg 2001; 88: 1066–1072.

133. Franklin IJ, et al. Vascular surgical society of great britain and ireland: non-steroidal anti-inflammatory drugs to treat abdominal aortic aneurysm. Br J Surg 1999; 86: 707.

134. Thompson SG, et al. Multicentre Aneurysm Screening Study Group. Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study. BMJ 2009; 338: b2307.

135. Schmidt T, et al. Benefit, risks and cost-effectiveness of screening for abdominal aortic aneurysm. Rofo 2010; 182: 573–580.

136. Lindholt JS, et al. Screening for abdominal aortic aneurysms: single centre randomised controlled trial. BMJ 2005; 330: 750.